_256_384.jpg)
Drug Approval | October 12, 2021
Covaxin for kids gets nod, final approval awaited
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Now all districts of the country will have commissioned PSA Oxygen plants
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
Subscribe To Our Newsletter & Stay Updated
